Crispr Therapeutics AG vs Super Micro Computer Inc — how do they compare? Crispr Therapeutics AG trades at $50.7 (market cap $4.97B), while Super Micro Computer Inc trades at $26.88 (market cap $17.89B). The key difference: Super Micro Computer Inc is far larger — about 3.6× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | SMCI | |
|---|---|---|
Market Cap | $4.97B | $17.89B |
Sector | Health | Technology |
52-Week High | $76.78 | $60.71 |
52-Week Low | $44.34 | $20.53 |
Enterprise Value | $3.32B | $25.40B |
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Super Micro Computer (SMCI) trades at $27.66, down 2.3% for the day, reflecting recent bearish pressure amid a 56% decline from its 52-week high. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong revenue growth to $22.0B in 2025 and beat earnings expectations in recent quarters, though net margins compressed to 3.7% in 2026. Recent news highlights challenges including a Taiwan probe into AI server exports and cash flow strain from inventory buildup.
The outlook for SMCI is cautious near-term due to operational and regulatory headwinds, but long-term potential remains tied to AI infrastructure demand. Investment opportunity exists if the company can improve cash conversion and navigate competitive pressures, while risks include execution missteps and further margin erosion. Analyst consensus suggests upside to a $36.71 price target, but investor sentiment is tempered by recent volatility.
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →